Abstract
Thirty-one psychiatric outpatients with tardive dyskinesia (TD) on neuroleptic medication were followed in a double-blind, randomized trial comparing baclofen (30–90 mg per day) to placebo. A repeated measures analysis of variance revealed no statistical difference between the baclofen-treated group and the placebo group for the group and the placebo group for the total Abnormal Involuntary Movement Scale (AIMS) scores. There was a trend (P=0.09) for an initial improvement, then a worsening of frequency counts across four visits. The authors attempt to explain this finding on the basis of information obtained from animal research.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Crane JE (1968) Tardive dyskinesia in patients treated with major neuroleptics: A review of the literature. Am J Psychiatry (Suppl):40–54
Endicott J, Spitzer RL (1979) A diagnostic interview: The schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35:837–844
Gerlach J (1977) The relationship between parkinsonism and tardive dyskinesia. Am J Psychiatry 134:781–784
Gerlach J, Rye T, Kristjansen P (1978) Effect of baclofen on tardive dyskinesia. Psychopharmacology 56:145–151
Glazer WM, Moore DC (1981) A tardive dyskinesia clinic in mental health center. Hosp Commun Psychiatry 32:572–574
Grace AA, Bunney BS (1980) Effects of baclofen on nigral dopaminergic cell activity following acute and chronic haloperidol treatment. GABA Neurotrans Br Res Bull 5 (Suppl 2):537–543
Gulmann NC, Bahr B, Anderson B, et al. (1976) A double blind trial of baclofen against placebo in the treatment of schizophrenia. Acta Psychiatr Scand 54:287–293
Hollister LE (1973) Clinical use of psychotherapeutic drugs. Charles C Thomas, Springfield IL
Itil TM, Herkert E, Schneider SJ, et al. (1980) Baclofen in the treatment of tardive dyskinesia: Open label study. Acta Therapeutica 6:315–323
Jeste DV, Wyatt RJ (1979) In search of treatment for tardive dyskinesia: A review of the literature. Schiz Bull 5:251–293
Klawans HL (1973) The pharmacology of tardive dyskinesia. Am J Psychiatry 130:82–86
Korsgaard S (1976) Baclofen (Lioresel) in the treatment of neuroleptic-induced tardive dyskinesia. Br J Psychiatry 129:114–119
Nair NPV, Yassa R, Ruiv-Navarro J, Schwartz G (1978) Baclofen in the treatment of tardive dyskinesia. Am J Psychiatry 135:1562–1563
Overall J, Gorham D (1967) Brief pschiatric rating scale. Psychol Rep 10:799–812
Richardson MA, Craig TJ, Branchey MH (1982) Intra-patient variability in the measurement of tardive dyskinesia. Psychopharmacology 76:269–272
Simpson GM, Lee H, Branchey MH, Shrivastavai RK (1978) Baclofen in the treatment of tardive dyskinesia. Psychopharmacol Bull 14:16–18
Smith JM, Jucharski LT, Oswald MA (1979) A systematic investigation of tardive dyskinesia in patients. Am J Pschiatry 136:918–922
Spitzer R, Endivott J (1978) Research diagnostic criteria, 3rd ed. State of New York, NY state psychiatric institute instrument no 59
Stewart MR, Collins J, Beckham B, Roffman M (1982) Baclofen in tardive dyskinesia patients maintained on neuroleptics. Clin Neuropharmacol 5:365–373
Author information
Authors and Affiliations
Additional information
UMDMJ-Rutgers Medical School and Department of Clinical Research, CIBA-GEIGY Corporation
Rights and permissions
About this article
Cite this article
Glazer, W.M., Moore, D.C., Bowers, M.B. et al. The treatment of tardive dyskinesia with baclofen. Psychopharmacology 87, 480–483 (1985). https://doi.org/10.1007/BF00432517
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00432517